Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MDH2 | P40926 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11793596 | 0.89 | CTNNB1 (0.49) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL12606659 | 0.87 | CTNNB1 (0.42) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL29464955 | 0.87 | ALDH1A1 (0.46) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL12606661 | 0.87 | PBRM1 (0.46) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL1350659 | 0.80 | KDM4E (0.67) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL2971998 | 0.80 | CYP1A2 (0.55) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL28638495 | 0.80 | HPGD (0.47) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL30065611 | 0.80 | HPGD (0.47) | CYP1A2HSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL11793589 | 0.80 | CTNNB1 (0.49) | ALDH1A1MEN1KMT2ACTNNB1WNT3A | |
| SCHEMBL397484 | 0.78 | CYP1A2 (0.56) | CYP1A2HSD17B10HPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| CN-102666546-B | Solid forms of N- (4- (7-azabicyclo [2.2.1] hept-7-yl) -2- (trifluoromethyl) phenyl) -4-oxo-5- (trifluoromethyl) -1, 4-dihydroquinoline-3-carboxamide | VERTEX PHARMACEUTICALS INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| US-20150164881-A1 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20100130547-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUORORMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYROQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010048573-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048564-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048526-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, SLC26A4 | CYP1A2 760/4885HSD17B10 1493/4885HPGD 1113/4885 |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | CYP1A2 3995/4885HSD17B10 2136/4885HPGD 1015/4885 |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, SLC26A4 | CYP1A2 760/4885HSD17B10 1493/4885HPGD 1113/4885 |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, ABCC5 | CYP1A2 789/4885HSD17B10 1386/4885HPGD 1372/4885 |
| US-20150164881-A1 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, ABCC5 | CYP1A2 789/4885HSD17B10 1386/4885HPGD 1372/4885 |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP1A2 3995/4885HSD17B10 2136/4885HPGD 1015/4885 |
| US-20100130547-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUORORMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYROQUINOLINE-3-CARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, AZI2 | CYP1A2 26/4885HSD17B10 2377/4885HPGD 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.